Cytomegalovirus appendicitis after hematopoietic stem cell transplantation.
Atul KothariKari D CaradineJuan Carlos Rico CrescencioAppalanaidu SasapuMuthu K VeeraputhiranYogesh JethavaMary J BurgessPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2017)
We present the case of a young man with acute lymphoblastic leukemia who developed cytomegalovirus (CMV) appendicitis after receiving alemtuzumab for acute refractory graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT). CMV appendicitis is a rare complication; and we are reporting the first case to our knowledge of CMV appendicitis following HSCT. Our case highlights the importance of recognition of CMV viral reactivation following the use of alemtuzumab. Using a preemptive strategy of checking CMV PCR, with initiation of early effective treatment on detection of CMV replication, may be appropriate following use of alemtuzumab in hematologic malignancies in patients after HSCT.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- acute myeloid leukemia
- end stage renal disease
- epstein barr virus
- ejection fraction
- liver failure
- newly diagnosed
- hematopoietic stem cell
- chronic kidney disease
- prognostic factors
- respiratory failure
- middle aged
- quantum dots
- electronic health record